Assoc. Prof. Dr. Agnieszka Majkowska-Pilip | Chemistry | Best Researcher Award
Professor at Institute of Nuclear Chemistry and Technology, Poland
Author Summary
Dr. Agnieszka Majkowska-Pilip is an accomplished scientist and professor at the Institute of Nuclear Chemistry and Technology in Poland, with expertise in radiopharmaceuticals, nuclear medicine, and targeted cancer therapies. Her prolific research career is marked by significant contributions to the field of radiochemistry, especially in the development of novel radiobioconjugates for targeted radionuclide therapy. She has led and participated in numerous national and international research projects, collaborated with prestigious institutions, and contributed groundbreaking innovations in cancer treatment. Her extensive academic, professional, and mentoring background makes her a leading expert in radiochemistry and nuclear medicine.
Professional profile
Education
Dr. Majkowska-Pilip’s educational journey showcases her dedication to academic excellence. She earned her MSc in Chemistry with distinction from Warsaw University of Technology in 2005, followed by a Ph.D. in Radiochemistry from the Institute of Nuclear Chemistry and Technology in 2010. Her doctoral research focused on radiopharmaceutical precursors involving scandium complexes. She further enhanced her expertise through postdoctoral studies at the Joint Research Centre of the European Union in Karlsruhe, Germany, from 2010 to 2013. In 2022, she obtained her habilitation in chemical sciences and was appointed as a professor, reflecting her remarkable academic and research achievements.
Professional Experience
Dr. Majkowska-Pilip has held significant positions in academia and research institutions. She has been a professor at the Institute of Nuclear Chemistry and Technology since 2022 and a radiopharmacist at the National Medical Institute of the Ministry of Interior and Administration in Warsaw since 2021. Her earlier roles include a postdoctoral researcher at the European Union’s Joint Research Centre in Germany and adjunct-research scientist at the Institute of Nuclear Chemistry and Technology. Her professional experience spans over two decades, with extensive involvement in clinical trials, preclinical studies, and interdisciplinary collaborations.
Research Interests
Dr. Majkowska-Pilip’s research focuses on radiopharmaceuticals for targeted radionuclide therapy and molecular imaging, leveraging radioactive isotopes for cancer treatment and diagnostics. Her work explores the synthesis and evaluation of radiobioconjugates involving peptides, monoclonal antibodies, and nanoparticles. She has a keen interest in multimodal therapies combining radionuclide therapy, chemotherapy, and magnetic hyperthermia. Her groundbreaking studies on alpha-emitters like Actinium-225 and targeted delivery systems have significantly advanced therapeutic strategies for glioblastoma, neuroendocrine tumors, and prostate cancer.
Research Skills
Dr. Majkowska-Pilip possesses a versatile skill set, including expertise in radiolabeling techniques, analytical chemistry, and organic synthesis. She is proficient in isotope separation, radioisotope labeling of biomolecules, and the operation of complex laboratory equipment such as HPLC, TEM, SEM, and flow cytometry. Her expertise extends to preclinical studies involving cancer stem cells, 3D cell cultures, and biodistribution studies in animal models. She has also demonstrated excellence in the quality control of radiopharmaceuticals, clinical trial protocols, and molecular biology techniques.
Awards and Honors
Dr. Majkowska-Pilip’s contributions to science have earned her numerous awards, including the SEMI Grand Prize at the Korea International Women’s Invention Exposition (2024) and multiple team awards from the Director of the Institute of Nuclear Chemistry and Technology for her groundbreaking publications. Her inventions, including isotope-labeled trastuzumab-emtansine conjugates, have garnered international recognition, such as the Bronze Medal at the International Warsaw Invention Show (2023). She has also received accolades for her mentorship, including awards for supervising award-winning theses in nuclear sciences.
Conclusion
Dr. Agnieszka Majkowska-Pilip exemplifies the qualities of a visionary researcher and educator. Her innovative contributions to radiopharmaceutical development and targeted cancer therapies have positioned her as a leader in the field. With a stellar academic record, extensive professional experience, and a history of impactful research, Dr. Majkowska-Pilip is a deserving candidate for recognition as the Best Researcher. Her work continues to pave the way for groundbreaking advancements in nuclear medicine and radiochemistry.
Publication Top Notes
- Title: Au@109Pd Core–Shell Nanoparticles Conjugated to Panitumumab for the Combined β−—Auger Electron Therapy of Triple-Negative Breast Cancer
Authors: Gharibkandi, N.A.; Majkowska-Pilip, A.; Walczak, R.; Wierzbicki, M.; Bilewicz, A.
Year: 2024
Citations: 0 - Title: 109Pd/109mAg In-Vivo Generator in the Form of Nanoparticles for Combined β− Auger Electron Therapy of Hepatocellular Carcinoma
Authors: Gharibkandi, N.A.; Wawrowicz, K.; Walczak, R.; Wierzbicki, M.; Bilewicz, A.
Year: 2024
Citations: 1 - Title: Au@109Pd Core–Shell Nanoparticle Conjugated to Trastuzumab for the Therapy of HER2+ Cancers: Studies on the Applicability of 109Pd/109mAg In-Vivo Generator in Combined β− Auger Electron Therapy
Authors: Gharibkandi, N.A.; Wawrowicz, K.; Majkowska-Pilip, A.; Wierzbicki, M.; Bilewicz, A.
Year: 2023
Citations: 3 - Title: Nanohydroxyapatite Loaded with 5-Fluorouracil and Calendula officinalis L. Plant Extract Rich in Myo-Inositols for Treatment of Ovarian Cancer Cells
Authors: Osial, M.; Wilczewski, S.; Szulc, J.; Kulus, D.; Giersig, M.
Year: 2023
Citations: 1 - Title: Improvement of the Effectiveness of HER2+ Cancer Therapy by Use of Doxorubicin and Trastuzumab Modified Radioactive Gold Nanoparticles
Authors: Żelechowska-Matysiak, K.; Salvanou, E.-A.; Bouziotis, P.; Bilewicz, A.; Majkowska-Pilip, A.
Year: 2023
Citations: 9 - Title: 5-Fluorouracil and Curcuminoids Extract from Curcuma longa L. Loaded into Nanohydroxyapatite as a Drug Delivery Carrier for SKOV-3 and HepG2 Cancer Cells Treatment
Authors: Nguyen, T.P.; Wilczewski, S.; Lewandowski, J.; Krysiński, P.; Osial, M.
Year: 2023
Citations: 6 - Title: Synthesis and Characterization of Sr2+ and Gd3+ Doped Magnetite Nanoparticles for Magnetic Hyperthermia and Drug Delivery Application
Authors: Olusegun, S.J.; Osial, M.; Majkowska-Pilip, A.; Pękała, M.; Krysiński, P.
Year: 2023
Citations: 16 - Title: Platinum Nanoparticles Labelled with Iodine-125 for Combined “Chemo-Auger Electron” Therapy of Hepatocellular Carcinoma
Authors: Wawrowicz, K.; Żelechowska-Matysiak, K.; Majkowska-Pilip, A.; Wierzbicki, M.; Bilewicz, A.
Year: 2023
Citations: 3 - Title: Doxorubicin- and Trastuzumab-Modified Gold Nanoparticles as Potential Multimodal Agents for Targeted Therapy of HER2+ Cancers
Authors: Żelechowska-Matysiak, K.; Wawrowicz, K.; Wierzbicki, M.; Bilewicz, A.; Majkowska-Pilip, A.
Year: 2023
Citations: 5 - Title: Multimodal Radiobioconjugates of Magnetic Nanoparticles Labeled with 44Sc and 47Sc for Theranostic Application
Authors: Ünak, P.; Yasakçı, V.; Tutun, E.; Majkowska-Pilip, A.; Bilewicz, A.
Year: 2023
Citations: 6